Clinical Overview of Tetrahydrocannabinol
Direct CB1 (Central Nervous System) & CB2 (Peripheral Immune) Agonist
Key Action
Vigorous analgesic, sleep inducer, and muscle anti-spasmodic.
Clinical Abstract
Delta-9-Tetrahydrocannabinol (THC) is the primary active agent in cannabis, mimicking the body's natural endocannabinoid Anandamide. By binding directly as a partial agonist to CB1 receptors clustered in brain gray matter (such as the basal ganglia and amygdala), THC effectively blocks ascending pain signaling pathways. At peripheral levels, its interaction with CB2 receptors on immune cells downregulates local cellular inflammation. While high dosages trigger psychotropic states, clinical micro-dosing (1-2.5mg) delivers profound therapeutic calming, muscular relaxation, and sleep-induction without cognitive disruption.
Physiological Mechanisms of Action
Target Clinical Indications
Dosing & Titration Protocols (“Start Low and Go Slow”)
Strict micro-dosing protocol is advised. Begin with a minute 1mg to 1.5mg dosage in the evening. Maintain for 5 days. If muscular spasms or sleep distress persist, increase slowly by 0.5mg. Do not exceed 5mg per single dose to protect CB1 receptor density.
Entourage Synergies & Secondary Phyto-coupling
Medical Study Source Citations:
Frontiers in Medicine (2022): Microdosage THC demonstrates up to 64% pain reduction without triggering psychoactive impairment, proving the efficiency of low-dose central nervous modulation.
